Investigational Drug Information for SGI-1776
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for SGI-1776?
SGI-1776 is an investigational drug.
There have been 27 clinical trials for SGI-1776.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 16th 2017.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Astex Pharmaceuticals, Astex Pharmaceuticals, Inc., and National Cancer Institute (NCI).
There are fifteen US patents protecting this investigational drug and sixty-eight international patents.
Summary for SGI-1776
| US Patents | 15 |
| International Patents | 68 |
| US Patent Applications | 76 |
| WIPO Patent Applications | 36 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 3 (2017-03-16) |
| Vendors | 75 |
Recent Clinical Trials for SGI-1776
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | National Cancer Institute (NCI) | Phase 2 |
| Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Astex Pharmaceuticals | Phase 1/Phase 2 |
| Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Astex Pharmaceuticals, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for SGI-1776
Top disease conditions for SGI-1776
Top clinical trial sponsors for SGI-1776
US Patents for SGI-1776
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SGI-1776 | See Plans and Pricing | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | See Plans and Pricing |
| SGI-1776 | See Plans and Pricing | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation (Wilmington, DE) | See Plans and Pricing |
| SGI-1776 | See Plans and Pricing | Pyrazolopyridine compounds and uses thereof | Incyte Corporation (Wilmington, DE) | See Plans and Pricing |
| SGI-1776 | See Plans and Pricing | Pyrazolopyridone compounds and uses thereof | Incyte Corporation (Wilmington, DE) | See Plans and Pricing |
| SGI-1776 | See Plans and Pricing | Pyrazolopyridine compounds and uses thereof | Incyte Corporation (Wilmington, DE) | See Plans and Pricing |
| SGI-1776 | See Plans and Pricing | Pyrrolotriazine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SGI-1776
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SGI-1776 | World Intellectual Property Organization (WIPO) | WO2017027717 | 2035-08-12 | See Plans and Pricing |
| SGI-1776 | World Intellectual Property Organization (WIPO) | WO2017035366 | 2035-08-26 | See Plans and Pricing |
| SGI-1776 | Argentina | AR109596 | 2036-09-09 | See Plans and Pricing |
| SGI-1776 | Australia | AU2017322427 | 2036-09-09 | See Plans and Pricing |
| SGI-1776 | Brazil | BR112019004586 | 2036-09-09 | See Plans and Pricing |
| SGI-1776 | Canada | CA3036358 | 2036-09-09 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
